Acarbose

Producers shown on SFDA

Producer:Shengxue Glucose Co., Ltd. of Shijiazhuang Pharmaceutical Group was established on March 30, 2002. Its business scope includes the production and sales of anhydrous glucose, starch, starch sugar, sorbitol, xylitol and other corn deep-processing products, amoxicillin synthetase, cephalosporin C acylase, penicillin acylase, cephalexin synthetase, sporaclor synthetase, ornithinase, citrullinase, guanidine butylamine, aspartic acid enzyme, ketoglutarate enzyme Cefradine synthetase, glutamine transaminase, cis acid isomerase, lipase, hyaluronidase, chiral ketoreductase, acarbose, biological bulk drugs (the above scope shall be operated within the validity period according to the items approved in the production license, except for precursor drugs of dangerous chemicals), and sales of special chemical products (except for dangerous chemicals)
Staff size:425persons

Registered capital:RMB 434.91 million 

Producer:Haizheng Pharmaceutical is a comprehensive pharmaceutical enterprise integrating research, production and marketing in the whole value chain, integration of APIs and preparations, and multi regional development. It was founded in 1956 and listed in 2000 with A-shares. It is a state-owned holding listed company. The company is one of the largest production bases of antibiotics and anti-tumor drugs in China, and has been listed among the top 500 manufacturing enterprises in China and the top 100 pharmaceutical enterprises in China for many times. In 2020, it was praised by the joint prevention and control group of the State Council as a well deserved "military factory" to fight against the epidemic, and won the title of "advanced collective of the industrial and information system to fight against COVID-19". Haizheng Pharmaceutical started from a chemical enterprise and has entered the pharmaceutical industry since the early 1970s. It has always adhered to the development of its main business for more than 60 years. Now, it has a total assets of 20 billion yuan and a sales scale of more than 10 billion yuan. The company focuses on the R&D, production and sales of innovative drugs, biological drugs, generic drugs and high-end APIs, covering more than 10 therapeutic fields such as anti-tumor, anti infection, cardiovascular, endocrine, immunosuppression, antidepressant, orthopedics, etc.

Staff size: 100-199persons

Registered capital:RMB 152 million 8 thousand and 551

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978